Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

TTT for RA Remained Stable over Post-Intervention

Arthritis Care Res; ePub 2018 Jan 5; Solomon, et al

Improvement in treat to target (TTT) for patients with rheumatoid arthritis (RA) remained relatively stable over a post-intervention period, according to a recent study. Researchers recruited 11 rheumatology sites (n=636 RA patients) and randomized them to either receive the Learning Collaborative (LC) during Phase I or to a wait-list control group that received the LC intervention during Phase II. The outcome was change in TTT implementation score (0 to 100, 100 is best) from pre- to post-intervention. Analyses examined: 1) the extent that the Phase I intervention teams sustained improvement in TTT; and, 2) predictors of TTT improvement. They found:

  • At baseline, mean TTT implementation score was 11% in Phase I intervention sites and 13% in Phase II sites.
  • After the intervention, TTT implementation score improved to 57% in the Phase I intervention sites and to 58% in the Phase II sites.
  • Intervention sites from Phase I sustained the improvement during the Phase II (52%).
  • Predictors of greater TTT improvement included only having rheumatologist providers at the site, academic affiliation of the site, fewer providers per site, and the rheumatologist provider being a trainee.

Citation:

Solomon DH, Lu B, Yu Z, et al. Benefits and sustainability of a Learning Collaborative for implementation of treat to target in rheumatoid arthritis: Results of the TRACTION Trial Phase II. [Published online ahead of print January 5, 2018]. Arthritis Care Res. doi:10.1002/acr.23508.